Author

Mark Baczkowski

Observed name: M. Baczkowski

Institution: Mylan (United States)

Observed institution: Mylan (United States)

OpenAlex ID: A5031417366

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer

2016 · Hope S. Rugo, Abhijit Barve, et al. · JAMA · 146

A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL‐1401O vs. EU‐trastuzumab and US‐trastuzumab

2018 · Cornelius F. Waller, Apinya Vutikullird, et al. · British Journal of Clinical Pharmacology · 30

A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim

2018 · Cornelius F. Waller, Renger G. Tiessen, et al. · Journal of Cancer Research and Clinical Oncology · 30

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia

2019 · Cornelius F. Waller, Gopinath M. Ranganna, et al. · Annals of Hematology · 25

A bioequivalence study of proposed bevacizumab biosimilar, MYL-1402O (A) vs EU-Avastin (B) and US-Avastin (C).

2017 · Mark A. Socinski, Matthew Hummel, et al. · Journal of Clinical Oncology · 6

A pharmacokinetics (PK) bioequivalence trial of proposed trastuzumab biosimilar, Myl-1401O (A) vs EU-Herceptin (B) and US-Herceptin (C)

2017 · C. Waller, A. Vutikullird, et al. · European Journal of Cancer · 5

Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-neulasta® in the prophylaxis of chemotherapy-induced neutropenia

2016 · C.F. Waller, C. Blakeley, et al. · Annals of Oncology · 5

A pharmacokinetics (PK) bioequivalence trial of proposed trastuzumab biosimilar, Myl-1401O (A) vs EU-Herceptin (B) and US-Herceptin (C).

2016 · Cornelius F. Waller, Apinya Vutikullird, et al. · Journal of Clinical Oncology · 5

A pharmacokinetics and pharmacodynamics equivalence trial of proposed pegfilgrastim biosimilar, MYL-1401H vs EU neulasta® and US neulasta®

2016 · C.F. Waller, R. Tiessen, et al. · Annals of Oncology · 3

Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-Neulasta ® in the prophylactic treatment of chemotherapy-induced neutropenia

2017 · C. Waller, C. Blakeley, et al. · European Journal of Cancer · 2

A pharmacokinetics and pharmacodynamics equivalence trial of proposed pegfilgrastim biosimilar, MYL-1401H vs EU-Neulasta ® and US-Neulasta ®

2017 · C. Waller, R. Tiessen, et al. · European Journal of Cancer

Works count: 11

Citation count: 257

H-index: 5

I10-index: 4